These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 21592855)

  • 1. A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B.
    Sonneveld MJ; Rijckborst V; Boucher CA; Zwang L; Beersma MF; Hansen BE; Janssen HL
    J Clin Virol; 2011 Jul; 51(3):175-8. PubMed ID: 21592855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum.
    Wursthorn K; Jaroszewicz J; Zacher BJ; Darnedde M; Raupach R; Mederacke I; Cornberg M; Manns MP; Wedemeyer H
    J Clin Virol; 2011 Apr; 50(4):292-6. PubMed ID: 21273117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
    Brunetto MR; Moriconi F; Bonino F; Lau GK; Farci P; Yurdaydin C; Piratvisuth T; Luo K; Wang Y; Hadziyannis S; Wolf E; McCloud P; Batrla R; Marcellin P
    Hepatology; 2009 Apr; 49(4):1141-50. PubMed ID: 19338056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of HBsAg and HBV-DNA during therapy with peginterferon alpha-2b plus lamivudine and peginterferon alpha-2b alone in a German chronic hepatitis B cohort.
    Wiegand J; Brosteanu O; Kullig U; Wiese M; Berr F; Maier M; Tillmann HL; Schiefke I
    Z Gastroenterol; 2011 Nov; 49(11):1463-9. PubMed ID: 22069045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum HBsAg levels during peginterferon α-2a treatment with or without thymosin α-1 in HBeAg-positive chronic hepatitis B patients.
    Song EY; Shin Y; Roh EY; Sue S; Park MH; Kim BH; Kim W; Yoon JH; Lee YJ; Park SJ; Jung EU; Lee JH; Myung SJ; Kim YJ; Lee HS
    J Med Virol; 2011 Jan; 83(1):88-94. PubMed ID: 21108343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
    Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
    Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.
    Sonneveld MJ; Rijckborst V; Boucher CA; Hansen BE; Janssen HL
    Hepatology; 2010 Oct; 52(4):1251-7. PubMed ID: 20830787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of hepatitis B surface antigen and E antigen: correlation between Elecsys and architect assays.
    Zhou B; Liu M; Lv G; Zheng H; Wang Y; Sun J; Hou J
    J Viral Hepat; 2013 Jun; 20(6):422-9. PubMed ID: 23647959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients.
    Chan HL; Wong GL; Chim AM; Chan HY; Chu SH; Wong VW
    Antivir Ther; 2011; 16(8):1249-57. PubMed ID: 22155906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of hepatitis B surface antigen with the novel DiaSorin LIAISON XL Murex HBsAg Quant: correlation with the ARCHITECT quantitative assays.
    Burdino E; Ruggiero T; Proietti A; Milia MG; Olivero A; Caviglia GP; Marietti M; Rizzetto M; Smedile A; Ghisetti V
    J Clin Virol; 2014 Aug; 60(4):341-6. PubMed ID: 24930708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.
    Chan HL; Wong VW; Tse AM; Tse CH; Chim AM; Chan HY; Wong GL; Sung JJ
    Clin Gastroenterol Hepatol; 2007 Dec; 5(12):1462-8. PubMed ID: 18054753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
    Peng CY; Lai HC; Li YF; Su WP; Chuang PH; Kao JT
    Aliment Pharmacol Ther; 2012 Feb; 35(4):458-68. PubMed ID: 22225574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.
    Sonneveld MJ; Rijckborst V; Zeuzem S; Heathcote EJ; Simon K; Senturk H; Pas SD; Hansen BE; Janssen HL
    Hepatology; 2012 Jul; 56(1):67-75. PubMed ID: 22307831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients.
    Gramenzi A; Loggi E; Micco L; Cursaro C; Fiorino S; Galli S; Gitto S; Galli C; Furlini G; Bernardi M; Andreone P
    J Viral Hepat; 2011 Oct; 18(10):e468-74. PubMed ID: 21914065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.
    Sonneveld MJ; Hansen BE; Piratvisuth T; Jia JD; Zeuzem S; Gane E; Liaw YF; Xie Q; Heathcote EJ; Chan HL; Janssen HL
    Hepatology; 2013 Sep; 58(3):872-80. PubMed ID: 23553752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
    Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
    J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the elecsys HBsAg II assay and the architect assay for quantification of hepatitis B surface antigen in chronic hepatitis B patients.
    Liao CC; Hsu CW; Gu PW; Yeh CT; Lin SM; Chiu CT
    Biomed J; 2015; 38(3):250-6. PubMed ID: 25355387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between Elecsys HBsAg II and Architect assays for quantification of serum hepatitis B surface antigen in Chinese patients with chronic hepatitis B.
    Liu WW; Wang AZ; Xie FY; Hu TT; Zhong Q; Huang S
    Clin Lab; 2015; 61(1-2):141-7. PubMed ID: 25807647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with serum hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy.
    Chen J; Wang Z; Zhou B; Wang Y; Hou J
    Antivir Ther; 2012; 17(1):71-9. PubMed ID: 22267471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.